Global Neurological Disease Treatment Market
Global Neurological Disease Treatment Market

Neurological Disease Treatment Comprehensive Study by Drugs (Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Antihypertensive, Anticoagulants, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Disorder (Parkinsonís Disease, Alzheimerís Disease, Epilepsy, Cerebrovascular Disease, Multiple Sclerosis, Others), End User (Adults, Children) Players and Region - Global Market Outlook to 2026

Neurological Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 242 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Neurological Disease Treatment?
A neurological disease is any medical complication that affects the nervous system that includes your brain, spinal cord, and other nerves. According to medical experts, symptoms of a neurological disease are possibly mild, such as muscle weakness, poor coordination, or changes in thinking patterns. It was also observed that in some cases symptoms are usually more noticeable, such as seizures, pain, and intellectual disability. According to the World Health Organization (WHO), the cerebrovascular diseases, which can manifest as a stroke, migraine, or headache is the common cause of concern for several patients. In addition to that about 80% of patients suffering from cerebrovascular diseases across the world have these symptoms.

The market study is broken down and major geographies with country level break-up.

The neurological disease treatment market is highly fragmented with the presence of many players worldwide. Some of the leading players are adopting some organic and inorganic strategies such as a merger, acquisition, expansion, new product launches, among others in order to gain leading share within the market. There are scopes for expansion with the surge in new improved products being launched owing to technological advancements Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global Neurological Disease Treatment market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), Novartis International AG (Switzerland), Merck & Co (United States), Boehringer Ingelheim (Germany), Bayer (Germany), Astra Zeneca (United Kingdom), F-Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Neurocrine Biosciences (United States) and Biogen (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are BioMarin Pharmaceutical (United States) and Otsuka America Pharmaceutical (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Neurological Disease Treatment market by Type, Application and Region.

On the basis of geography, the market of Neurological Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Antipsychotic will boost the Neurological Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Neurological Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder, the sub-segment i.e. Parkinsonís Disease will boost the Neurological Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Adults will boost the Neurological Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disease

Market Drivers
  • Rising prevalence of neurological diseases coupled with increasing awareness associated with the disease diagnosis in developing countries is assisting the market growth

Opportunities
  • Breakthrough research in neurological disease can provide pharmaceuticals companies with increased opportunities for their market growth
  • Growing neurological disorders worldwide can provide emerging prospects for drug retailers and other treatment

Restraints
  • Stringent government regulations for approval of drugs

Challenges
  • Research and development initiatives for drug formulations are expensive
  • Provision of affordable drugs inconsideration with developing and underdeveloped countries


Key Target Audience
Pharmaceutical Companies, Pharmacy Chains/Drug Stores, Drug Suppliers/Traders, Drug Exporters/Importers, Investors, Regulatory and Government Bodies, Upstream Vendors, Downstream Vendors and Others

About Approach
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Drugs
  • Antipsychotic
  • Antiepileptic
  • Anticholinergic
  • Analgesics
  • Hypnotic and Sedative
  • Antihypertensive
  • Anticoagulants
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Disorder
  • Parkinsonís Disease
  • Alzheimerís Disease
  • Epilepsy
  • Cerebrovascular Disease
  • Multiple Sclerosis
  • Others

By End User
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of neurological diseases coupled with increasing awareness associated with the disease diagnosis in developing countries is assisting the market growth
    • 3.3. Market Challenges
      • 3.3.1. Research and development initiatives for drug formulations are expensive
      • 3.3.2. Provision of affordable drugs inconsideration with developing and underdeveloped countries
    • 3.4. Market Trends
      • 3.4.1. The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disease
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurological Disease Treatment, by Drugs, Distribution Channel, Disorder, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neurological Disease Treatment (Value)
      • 5.2.1. Global Neurological Disease Treatment by: Drugs (Value)
        • 5.2.1.1. Antipsychotic
        • 5.2.1.2. Antiepileptic
        • 5.2.1.3. Anticholinergic
        • 5.2.1.4. Analgesics
        • 5.2.1.5. Hypnotic and Sedative
        • 5.2.1.6. Antihypertensive
        • 5.2.1.7. Anticoagulants
        • 5.2.1.8. Others
      • 5.2.2. Global Neurological Disease Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Neurological Disease Treatment by: Disorder (Value)
        • 5.2.3.1. Parkinsonís Disease
        • 5.2.3.2. Alzheimerís Disease
        • 5.2.3.3. Epilepsy
        • 5.2.3.4. Cerebrovascular Disease
        • 5.2.3.5. Multiple Sclerosis
        • 5.2.3.6. Others
      • 5.2.4. Global Neurological Disease Treatment by: End User (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Children
      • 5.2.5. Global Neurological Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Neurological Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astra Zeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F-Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neurocrine Biosciences (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neurological Disease Treatment Sale, by Drugs, Distribution Channel, Disorder, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neurological Disease Treatment (Value)
      • 7.2.1. Global Neurological Disease Treatment by: Drugs (Value)
        • 7.2.1.1. Antipsychotic
        • 7.2.1.2. Antiepileptic
        • 7.2.1.3. Anticholinergic
        • 7.2.1.4. Analgesics
        • 7.2.1.5. Hypnotic and Sedative
        • 7.2.1.6. Antihypertensive
        • 7.2.1.7. Anticoagulants
        • 7.2.1.8. Others
      • 7.2.2. Global Neurological Disease Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Neurological Disease Treatment by: Disorder (Value)
        • 7.2.3.1. Parkinsonís Disease
        • 7.2.3.2. Alzheimerís Disease
        • 7.2.3.3. Epilepsy
        • 7.2.3.4. Cerebrovascular Disease
        • 7.2.3.5. Multiple Sclerosis
        • 7.2.3.6. Others
      • 7.2.4. Global Neurological Disease Treatment by: End User (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Children
      • 7.2.5. Global Neurological Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurological Disease Treatment: by Drugs(USD Million)
  • Table 2. Neurological Disease Treatment Antipsychotic , by Region USD Million (2015-2020)
  • Table 3. Neurological Disease Treatment Antiepileptic , by Region USD Million (2015-2020)
  • Table 4. Neurological Disease Treatment Anticholinergic , by Region USD Million (2015-2020)
  • Table 5. Neurological Disease Treatment Analgesics , by Region USD Million (2015-2020)
  • Table 6. Neurological Disease Treatment Hypnotic and Sedative , by Region USD Million (2015-2020)
  • Table 7. Neurological Disease Treatment Antihypertensive , by Region USD Million (2015-2020)
  • Table 8. Neurological Disease Treatment Anticoagulants , by Region USD Million (2015-2020)
  • Table 9. Neurological Disease Treatment Others , by Region USD Million (2015-2020)
  • Table 10. Neurological Disease Treatment: by Distribution Channel(USD Million)
  • Table 11. Neurological Disease Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Neurological Disease Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Neurological Disease Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Neurological Disease Treatment: by Disorder(USD Million)
  • Table 15. Neurological Disease Treatment Parkinsonís Disease , by Region USD Million (2015-2020)
  • Table 16. Neurological Disease Treatment Alzheimerís Disease , by Region USD Million (2015-2020)
  • Table 17. Neurological Disease Treatment Epilepsy , by Region USD Million (2015-2020)
  • Table 18. Neurological Disease Treatment Cerebrovascular Disease , by Region USD Million (2015-2020)
  • Table 19. Neurological Disease Treatment Multiple Sclerosis , by Region USD Million (2015-2020)
  • Table 20. Neurological Disease Treatment Others , by Region USD Million (2015-2020)
  • Table 21. Neurological Disease Treatment: by End User(USD Million)
  • Table 22. Neurological Disease Treatment Adults , by Region USD Million (2015-2020)
  • Table 23. Neurological Disease Treatment Children , by Region USD Million (2015-2020)
  • Table 24. South America Neurological Disease Treatment, by Country USD Million (2015-2020)
  • Table 25. South America Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 26. South America Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 27. South America Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 28. South America Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 29. Brazil Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 30. Brazil Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. Brazil Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 32. Brazil Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 33. Argentina Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 34. Argentina Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 35. Argentina Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 36. Argentina Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 37. Rest of South America Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 38. Rest of South America Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 39. Rest of South America Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 40. Rest of South America Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 41. Asia Pacific Neurological Disease Treatment, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 43. Asia Pacific Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 44. Asia Pacific Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 45. Asia Pacific Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 46. China Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 47. China Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 48. China Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 49. China Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 50. Japan Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 51. Japan Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Japan Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 53. Japan Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 54. India Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 55. India Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. India Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 57. India Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 58. South Korea Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 59. South Korea Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 60. South Korea Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 61. South Korea Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 62. Taiwan Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 63. Taiwan Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 64. Taiwan Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 65. Taiwan Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 66. Australia Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 67. Australia Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 68. Australia Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 69. Australia Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 74. Europe Neurological Disease Treatment, by Country USD Million (2015-2020)
  • Table 75. Europe Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 76. Europe Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 77. Europe Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 78. Europe Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 79. Germany Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 80. Germany Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 81. Germany Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 82. Germany Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 83. France Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 84. France Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 85. France Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 86. France Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 87. Italy Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 88. Italy Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 89. Italy Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 90. Italy Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 91. United Kingdom Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 92. United Kingdom Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 93. United Kingdom Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 94. United Kingdom Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 95. Netherlands Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 96. Netherlands Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 97. Netherlands Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 98. Netherlands Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 99. Rest of Europe Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 100. Rest of Europe Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 101. Rest of Europe Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 102. Rest of Europe Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 103. MEA Neurological Disease Treatment, by Country USD Million (2015-2020)
  • Table 104. MEA Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 105. MEA Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 106. MEA Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 107. MEA Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 108. Middle East Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 109. Middle East Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 110. Middle East Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 111. Middle East Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 112. Africa Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 113. Africa Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 114. Africa Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 115. Africa Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 116. North America Neurological Disease Treatment, by Country USD Million (2015-2020)
  • Table 117. North America Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 118. North America Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 119. North America Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 120. North America Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 121. United States Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 122. United States Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 123. United States Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 124. United States Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 125. Canada Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 126. Canada Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 127. Canada Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 128. Canada Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 129. Mexico Neurological Disease Treatment, by Drugs USD Million (2015-2020)
  • Table 130. Mexico Neurological Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 131. Mexico Neurological Disease Treatment, by Disorder USD Million (2015-2020)
  • Table 132. Mexico Neurological Disease Treatment, by End User USD Million (2015-2020)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Neurological Disease Treatment: by Drugs(USD Million)
  • Table 144. Neurological Disease Treatment Antipsychotic , by Region USD Million (2021-2026)
  • Table 145. Neurological Disease Treatment Antiepileptic , by Region USD Million (2021-2026)
  • Table 146. Neurological Disease Treatment Anticholinergic , by Region USD Million (2021-2026)
  • Table 147. Neurological Disease Treatment Analgesics , by Region USD Million (2021-2026)
  • Table 148. Neurological Disease Treatment Hypnotic and Sedative , by Region USD Million (2021-2026)
  • Table 149. Neurological Disease Treatment Antihypertensive , by Region USD Million (2021-2026)
  • Table 150. Neurological Disease Treatment Anticoagulants , by Region USD Million (2021-2026)
  • Table 151. Neurological Disease Treatment Others , by Region USD Million (2021-2026)
  • Table 152. Neurological Disease Treatment: by Distribution Channel(USD Million)
  • Table 153. Neurological Disease Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 154. Neurological Disease Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 155. Neurological Disease Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 156. Neurological Disease Treatment: by Disorder(USD Million)
  • Table 157. Neurological Disease Treatment Parkinsonís Disease , by Region USD Million (2021-2026)
  • Table 158. Neurological Disease Treatment Alzheimerís Disease , by Region USD Million (2021-2026)
  • Table 159. Neurological Disease Treatment Epilepsy , by Region USD Million (2021-2026)
  • Table 160. Neurological Disease Treatment Cerebrovascular Disease , by Region USD Million (2021-2026)
  • Table 161. Neurological Disease Treatment Multiple Sclerosis , by Region USD Million (2021-2026)
  • Table 162. Neurological Disease Treatment Others , by Region USD Million (2021-2026)
  • Table 163. Neurological Disease Treatment: by End User(USD Million)
  • Table 164. Neurological Disease Treatment Adults , by Region USD Million (2021-2026)
  • Table 165. Neurological Disease Treatment Children , by Region USD Million (2021-2026)
  • Table 166. South America Neurological Disease Treatment, by Country USD Million (2021-2026)
  • Table 167. South America Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 168. South America Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. South America Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 170. South America Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 171. Brazil Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 172. Brazil Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 173. Brazil Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 174. Brazil Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 175. Argentina Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 176. Argentina Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 177. Argentina Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 178. Argentina Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 179. Rest of South America Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 180. Rest of South America Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 181. Rest of South America Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 182. Rest of South America Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 183. Asia Pacific Neurological Disease Treatment, by Country USD Million (2021-2026)
  • Table 184. Asia Pacific Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 185. Asia Pacific Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 186. Asia Pacific Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 187. Asia Pacific Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 188. China Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 189. China Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 190. China Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 191. China Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 192. Japan Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 193. Japan Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 194. Japan Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 195. Japan Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 196. India Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 197. India Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. India Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 199. India Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 200. South Korea Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 201. South Korea Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 202. South Korea Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 203. South Korea Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 204. Taiwan Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 205. Taiwan Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Taiwan Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 207. Taiwan Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 208. Australia Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 209. Australia Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 210. Australia Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 211. Australia Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 216. Europe Neurological Disease Treatment, by Country USD Million (2021-2026)
  • Table 217. Europe Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 218. Europe Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 219. Europe Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 220. Europe Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 221. Germany Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 222. Germany Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 223. Germany Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 224. Germany Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 225. France Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 226. France Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 227. France Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 228. France Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 229. Italy Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 230. Italy Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 231. Italy Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 232. Italy Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 233. United Kingdom Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 234. United Kingdom Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 235. United Kingdom Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 236. United Kingdom Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 237. Netherlands Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 238. Netherlands Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 239. Netherlands Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 240. Netherlands Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 241. Rest of Europe Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 242. Rest of Europe Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 243. Rest of Europe Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 244. Rest of Europe Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 245. MEA Neurological Disease Treatment, by Country USD Million (2021-2026)
  • Table 246. MEA Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 247. MEA Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 248. MEA Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 249. MEA Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 250. Middle East Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 251. Middle East Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 252. Middle East Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 253. Middle East Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 254. Africa Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 255. Africa Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 256. Africa Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 257. Africa Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 258. North America Neurological Disease Treatment, by Country USD Million (2021-2026)
  • Table 259. North America Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 260. North America Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 261. North America Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 262. North America Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 263. United States Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 264. United States Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 265. United States Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 266. United States Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 267. Canada Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 268. Canada Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 269. Canada Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 270. Canada Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 271. Mexico Neurological Disease Treatment, by Drugs USD Million (2021-2026)
  • Table 272. Mexico Neurological Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 273. Mexico Neurological Disease Treatment, by Disorder USD Million (2021-2026)
  • Table 274. Mexico Neurological Disease Treatment, by End User USD Million (2021-2026)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurological Disease Treatment: by Drugs USD Million (2015-2020)
  • Figure 5. Global Neurological Disease Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Neurological Disease Treatment: by Disorder USD Million (2015-2020)
  • Figure 7. Global Neurological Disease Treatment: by End User USD Million (2015-2020)
  • Figure 8. South America Neurological Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Neurological Disease Treatment Share (%), by Country
  • Figure 10. Europe Neurological Disease Treatment Share (%), by Country
  • Figure 11. MEA Neurological Disease Treatment Share (%), by Country
  • Figure 12. North America Neurological Disease Treatment Share (%), by Country
  • Figure 13. Global Neurological Disease Treatment share by Players 2020 (%)
  • Figure 14. Global Neurological Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Neurological Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 21. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co (United States) Revenue: by Geography 2020
  • Figure 23. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 25. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer (Germany) Revenue: by Geography 2020
  • Figure 27. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Astra Zeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 29. F-Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F-Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 33. Neurocrine Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. Neurocrine Biosciences (United States) Revenue: by Geography 2020
  • Figure 35. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 36. Biogen (United States) Revenue: by Geography 2020
  • Figure 37. Global Neurological Disease Treatment: by Drugs USD Million (2021-2026)
  • Figure 38. Global Neurological Disease Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 39. Global Neurological Disease Treatment: by Disorder USD Million (2021-2026)
  • Figure 40. Global Neurological Disease Treatment: by End User USD Million (2021-2026)
  • Figure 41. South America Neurological Disease Treatment Share (%), by Country
  • Figure 42. Asia Pacific Neurological Disease Treatment Share (%), by Country
  • Figure 43. Europe Neurological Disease Treatment Share (%), by Country
  • Figure 44. MEA Neurological Disease Treatment Share (%), by Country
  • Figure 45. North America Neurological Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis International AG (Switzerland)
  • Merck & Co (United States)
  • Boehringer Ingelheim (Germany)
  • Bayer (Germany)
  • Astra Zeneca (United Kingdom)
  • F-Hoffmann-La Roche Ltd. (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Neurocrine Biosciences (United States)
  • Biogen (United States)
Additional players considered in the study are as follows:
BioMarin Pharmaceutical (United States) , Otsuka America Pharmaceutical (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation